METHODS OF TREATING ACNE

• US 20150297618A1
• Filed: 06/29/2015
• Published: 10/22/2015
• Est. Priority Date: 04/05/2001
• Status: Active Grant

• Current Assignee: Galderma Laboratories Incorporated (Nestle SA)
• Original Assignee: Galderma Laboratories Incorporated (Nestle SA)
• Inventors: Ashley, Robert A.
• Granted Patent: US 9,241,946 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/65 Tetracyclines
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61P 17/10 Anti-acne agents
• CPC Class Codes: D06M 16/00 Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic

Abstract

A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.

Claims

1. A method for treating acne in a human in need thereof, the method comprising

administering orally to said human doxycycline, or a pharmaceutically acceptable salt thereof,

in an amount that

(i) is effective to treat acne;

(ii) is 10-80% of a 50 mg dose of doxycycline; and

(iii) results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound.

2. The method according to claim 1, wherein said doxycycline is doxycycline monohydrate.

3. The method according to claim 2, wherein said doxycycline monohydrate is administered in an amount of 40 milligrams.

4. The method according to claim 3, wherein said doxycycline monohydrate is administered by sustained release.

5. A method according to claim 4, wherein said doxycycline monohydrate is administered once a day.

6. The method according to claim 2, wherein said doxycycline monohydrate is administered in a dose of 20 mg twice a day.

7. The method according to claim 1, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 μ

g/ml.

8. A method for treating acne in a human in need thereof, the method comprising

administering orally to said human doxycycline, or a pharmaceutically acceptable salt thereof,

in an amount that

(i) is effective to treat acne;

(ii) is 40-80% of a 50 mg dose of doxycycline; and

(iii) results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound.

9. The method according to claim 8, wherein said doxycycline is doxycycline monohydrate.

10. The method according to claim 9, wherein said doxycycline monohydrate is administered in an amount of 40 milligrams.

11. The method according to claim 10, wherein said doxycycline monohydrate is administered by sustained release.

12. A method according to claim 11, wherein said doxycycline monohydrate is administered once a day.

13. The method according to claim 9, wherein said doxycycline monohydrate is administered in a dose of 20 mg twice a day.

14. The method according to claim 8, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 μ

g/ml.

15. A method for treating acne in a human in need thereof, the method comprising

administering orally to said human doxycycline, or a pharmaceutically acceptable salt thereof, in an amount of 40 mg per day, wherein the amount results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound.

16. The method according to claim 15, wherein said doxycycline is doxycycline monohydrate.

17. The method according to claim 16, wherein said doxycycline monohydrate is administered by sustained release.

18. A method according to claim 17, wherein said doxycycline monohydrate is administered once a day.

19. The method according to claim 16, wherein said doxycycline monohydrate is administered in a dose of 20 mg twice a day.

20. The method according to claim 15, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 μ

g/ml.